Candriam Equities L Biotechnology R-Acc

Reference Data

ISIN LU0942225912
Valor Number 21612660
Bloomberg Global ID
Fund Name Candriam Equities L Biotechnology R-Acc
Fund Provider CANDRIAM Serenity, Bloc - B, 19-21, route d'Arlon
8009 Strassen
E-Mail: CH@Candriam.com
Phone: + 352 2797-1
Web: https://www.candriam.com
Fund Provider CANDRIAM
Representative in Switzerland CACEIS (Switzerland) SA
Nyon
Phone: +41 22 360 94 00
Distributor(s)
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund.
Peculiarities

Fund Prices

Current Price * 258.72 USD 31.03.2025
Previous Price * 264.67 USD 28.03.2025
52 Week High * 307.14 USD 08.11.2024
52 Week Low * 248.00 USD 19.04.2024
NAV * 258.72 USD 31.03.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 1,358,231,399
Unit/Share Assets *** 31,783,125
Trading Information SIX

Performance

YTD Performance -4.51% 31.12.2024
31.03.2025
YTD Performance (in CHF) -6.98% 31.12.2024
31.03.2025
1 month -6.94% 28.02.2025
31.03.2025
3 months -4.51% 31.12.2024
31.03.2025
6 months -11.99% 30.09.2024
31.03.2025
1 year -1.54% 02.04.2024
31.03.2025
2 years +9.56% 31.03.2023
31.03.2025
3 years +13.42% 31.03.2022
31.03.2025
5 years +40.83% 31.03.2020
31.03.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Gilead Sciences Inc 7.48%
Amgen Inc 6.31%
Regeneron Pharmaceuticals Inc 5.92%
Vertex Pharmaceuticals Inc 5.83%
Alnylam Pharmaceuticals Inc 3.99%
BioNTech SE ADR 3.26%
Insmed Inc 2.73%
Ascendis Pharma AS ADR 2.52%
BeiGene Ltd ADR 2.48%
Biomarin Pharmaceutical Inc 2.34%
Last data update 28.02.2025

Cost / Risk

TER *** 1.11%
TER date *** 30.06.2024
Performance Fee ***
PTR
Max. Management Fee *** 0.90%
Ongoing Charges *** 1.11%
SRRI ***
SRRI date *** 28.02.2025

Breakdowns

Countries ***

Created with Highstock 2.1.1075.2% United States6.2% Denmark3.9% United Kingdom3.4% Germany2.6% China2.3% Belgium2.1% Netherlands1.4% Canada1.3% Switzerland1.7% Others

Stock Sectors ***

Created with Highstock 2.1.10100.0% Healthcare

Bond Sectors ***

Created with Highstock 2.1.10100.0% Cash & Equivalents

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)